Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US ...
FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading ...
Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
Patients with Crohn disease report high satisfaction and minimal discomfort using the citrate-free biosimilar CT-P17, enhancing adherence to treatment. As health systems continue expanding the use of ...
New research reveals that switching from originator to biosimilar adalimumab for hidradenitis suppurativa may lead to reduced treatment effectiveness and stability. People living with hidradenitis ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback